UK approves Xevudy a new Covid-19 drug which reduces Covid deaths by 79%



The ‘Medicines and Healthcare products Regulatory Agency’ (MHRA) of the UK has approved Xevudy (a brand name for Sotrovimab), a new Covid drug for the treatment of patients.

The agency announced the news in a statement by further adding that the drug is very effective for Covid-19 patients with mild to moderate symptoms which might get severe over time.

In a clinical trial conducted, it was found that a single dose of the drug cut down the risk of hospitalization and death by 79% in adults with a high risk of COVID-19 infection.

After approving Ronapreve in August this year, a similar ‘monoclonal antibody therapeutic’ drug, this is the second such drug to be green signaled by the agency.



Copyright 2023 © Insightscare Magazine ( a Digital Ink brand ) All rights reserved.